Comparison of excretion of nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man.
We tested an inexpensive controlled-release nicotinic acid product (Bronson Pharmaceuticals, LaCanada, CA) and compared it with the standard, more expensive, controlled release product, Nicobid (Rorer Pharmaceuticals), by measuring the 24 hour urinary recovery of nicotinic and nicotinuric acids from ten subjects following 500 mg oral ingestion of each product. Nicotinuric acid is the major detoxification product of nicotinic acid and may serve as a simple quantitative index of hepatic biotransformation of nicotinic acid. Although both products demonstrated controlled release profiles, the rate of appearance of nicotinic and nicotinuric acid in the urine as well as the rate of in vitro drug dissolution of the Bronson product were more rapid compared with Nicobid. Moreover, the total amounts of nicotinic acid and nicotinuric acid recovered in the urine after 24 hours were greater for the Bronson product (P less than .05). Since sustained presentation of nicotinic acid to the liver may correlate with clinical antihyperlipidemic effects, our results suggest that the Bronson product may prove to be a clinically useful preparation.
Figge
H L
HL
Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts.
Figge
J
J
Souney
P F
PF
Sacks
F M
FM
Shargel
L
L
Janosik
J E
JE
Kaul
A F
AF
D000328:Adult; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D006801:Humans; D008297:Male; D009525:Niacin / Q000008:administration & dosage / Q000378:metabolism* / Q000652:urine; D009539:Nicotinic Acids / Q000652:urine*; D012995:Solubility; D013607:Tablets
D003692:Delayed-Action Preparations; D009539:Nicotinic Acids; D013607:Tablets; D009525:Niacin; C002477:nicotinuric acid